"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...
AZoLifeSciences on MSN2d
Integrating CRISPR and biomaterials engineering: Paving the way for safer gene therapiesLehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...
The scientific team at the laboratory is headed by a group of women with a track record in genomic science, molecular ...
2d
Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...
Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback